Low-dose methotrexate (MTX) is widely used in autoimmune diseases because of its anti-inflammatory activity. We report here the results of a retrospective study to review the outcomes of low-dose MTX used for treatment of refractory chronic graft-versus-host disease GVHD, with the goal of reducing the amount of prednisone needed to control the disease. In all, 14 patients with refractory chronic GVHD received MTX at a dose of 7.5 mg/m 2 / weekly for 3-50 weeks. Eleven patients had skin involvement, often with scleroderma or fasciitis. The median duration of chronic GVHD at the start of MTX was 38 (range 1-135) months. In this retrospective review, we found no grade 3-4 toxicities, and none of the patients needed blood transfusion or growth factors. In 10 patients (71%), GVHD could be adequately controlled with prednisone at doses below 1 mg/kg every other day without the addition of other agents. Four patients decreased the amount of concomitant immunosuppressive treatment, five continued with the same regimen, four required an increase in immunosuppressive treatment, and one decided to discontinue all treatment. From this preliminary analysis, MTX appears to be a well-tolerated, inexpensive and possibly steroid-sparing agent that is worthy of further evaluation in prospective trials for treatment of chronic GVHD.
/ weekly for 3-50 weeks. Eleven patients had skin involvement, often with scleroderma or fasciitis. The median duration of chronic GVHD at the start of MTX was 38 (range 1-135) months. In this retrospective review, we found no grade 3-4 toxicities, and none of the patients needed blood transfusion or growth factors. In 10 patients (71%), GVHD could be adequately controlled with prednisone at doses below 1 mg/kg every other day without the addition of other agents. Four patients decreased the amount of concomitant immunosuppressive treatment, five continued with the same regimen, four required an increase in immunosuppressive treatment, and one decided to discontinue all treatment. From this preliminary analysis, MTX appears to be a well-tolerated, inexpensive and possibly steroid-sparing agent that is worthy of further evaluation in prospective trials for treatment of chronic GVHD. Chronic graft-versus-host disease (GVHD) is the most common complication among patients who survive beyond 100 days after allogeneic hematopoietic cell transplantation (HCT). This complication occurs in up to 60% of patients with HLA-identical sibling donors and in 70% of those with unrelated or HLA-mismatched related donors. [1] [2] [3] Furthermore, chronic GVHD and its associated immunodeficiency and infection are the most frequent causes of late morbidity and nonrelapse mortality following HCT. Treatment with cyclosporine and glucocorticoids can control manifestations of chronic GVHD in some patients, but therapeutic options are limited for those with steroidrefractory chronic GVHD.
Methotrexate (MTX) is an antimetabolite with antiinflammatory and antiproliferative activity. When given at low doses (7.5 mg/m 2 /weekly), MTX has no cytotoxic effects, but instead has immunomodulatory and antiinflammatory properties 4 mediated through release of adenosine, 5 which binds to A 2 receptors and inhibits the oxidative burst in activated neutrophils and the adhesion of neutrophils to endothelial cells. Adenosine also modifies cytokine production by neutrophils, monocytes, macrophages and T lymphocytes, decreasing production of TNFa, IFN-a IL-6 and IL-8, and increasing production of IL-10 and IL-4. [4] [5] [6] As the biochemical action of low-dose MTX is not based on the inhibition of DHFR and DNA synthesis, folate supplementation does not affect its immunomodulatory effects.
MTX is converted intracellularly from monoglutamated derivatives to polyglutamated derivatives. Polyglutamates are retained inside cells for long periods of time, which explains the efficacy of the low-dose weekly regimen. 7 Compared to monoglutamates, polyglutamates have much greater affinity for enzymes requiring folates and are less reversible inhibitors of thymidylate synthetase and enzymes involved in purine synthesis. After oral administration, MTX is easily absorbed from the gastrointestinal tract. Blood levels peak between 1-5 h after oral administration, and MTX levels exceed 1 Â 10 À7 M for only about 6 h. 8, 9 The threshold of sensitivity to MTX anti-inflammatory effect has not been established, but 1 Â 10 À7 M MTX is required to inhibit DNA synthesis. 8 Weekly low-dose MTX (7.5-25 mg per week) has been widely and successfully used for treatment of patients with advance rheumatoid arthritis and other autoimmune diseases. [10] [11] [12] Given these results and the lack of accepted alternatives, we have used low-dose MTX for treatment of chronic GVHD that was refractory to steroids, calcineurin inhibitors, and other therapies. In this retrospective study, we reviewed our experience with the use of weekly low-dose MTX for the management of refractory chronic GVHD, with the goals of identifying possible drug toxicity and evaluating potential efficacy. ) at weekly intervals. In most cases, the decision to use MTX was based on clinical judgment that chronic GVHD was not responsive to standard therapy with glucocorticoids and a calcineurin inhibitor. In one case, MTX was used for initial therapy in a patient with progressive scleroderma and fasciitis because the patient could not tolerate 1 mg/kg of prednisone, and because other commonly used immunosuppressive agents have not been highly effective for treating sclerodermatous GVHD in the absence of concomitant steroid treatment. Owing to the teratogenicity of MTX, 13 women who were at risk of pregnancy were instructed to use contraception during administration of MTX and for 6 months afterwards. Patients were informed about the risks, benefits and uncertain outcomes with the use of MTX, and alternatives were also explained.
Patients and methods

Between
Institutional Review Board approval was obtained for review of medical records. Two of the 16 patients were excluded from the analysis because information was insufficient to assess toxicity and response. Characteristics of the remaining 14 patients are summarized in Table 1 . One patient received donor lymphocyte infusion 2.3 years after HCT for treatment of recurrent malignancy.
Results of complete blood counts, liver function tests, and renal function tests were of particular interest. Unexplained gastrointestinal, constitutional and neurological symptoms, and major infections were recorded as possibly related to MTX. The National Cancer Institute toxicity rating scale for bone marrow transplantation version 3.0 was used to grade the severity of side effects.
Treatments for chronic GVHD were counted from start of initial therapy until the date of MTX initiation. Changes in treatment were enumerated whenever a new systemic immunosuppressive treatment was started, whenever the dose of prednisone was increased from o0.5 to 1 mg/kg or more every other day, or whenever new therapy was added or systemic immunosuppressive treatment was reinstituted after earlier discontinuation. 14 Chronic GVHD manifestations were assessed before beginning treatment with MTX and either at the end of MTX treatment or at the date of last contact, whichever occurred first. We used an established four-point scale in which manifestations were scored as absent, as causing no functional impairment, as causing functional impairment without disability, or as causing disability. 15 Complete resolution at any site was defined as disappearance of GVHD manifestations, while changes in the score for each organ were classified as improvement or progression when manifestations were still present at the end of follow-up.
Results
In all, 14 patients were treated with MTX, 13 with progressive (n ¼ 8) or unimproved (n ¼ 5) chronic GVHD despite prior treatment with other systemic immunosuppressive agents and one with progressive chronic GVHD that had not been previously treated. The characteristics of chronic GVHD at the beginning of treatment with MTX are summarized in Table 2 . The most frequently involved sites were oral mucosa (n ¼ 14) and skin (n ¼ 11). In all, 12 patients had at least one feature of severe chronic GVHD, most often scleroderma with a median Rodnan score 16 of 3.5 (range 1-13.5).
MTX was administered weekly at a median dose of 10 mg (range, 7.5-15 mg) for a median of 25 weeks (range, 3-50 weeks). The median cumulative MTX dose among the 14 patients was 251 mg (range, 29-620 mg). The drug was administered orally in 12 patients, and two patients took MTX intravenously because of concern that absorption might be limited by severe gut GVHD. Both patients with gut GVHD had histological documentation of the disease and concomitant manifestation of chronic GVHD involving the mouth and skin (one patient) and eyes and mouth (one patient). All but one of the patients were treated concomitantly with trimethoprim-sulfamethoxazole daily (n ¼ 6) or weekly (n ¼ 7), and eight were given prophylactic oral folate supplementation (1-5 mg daily), as recommended with the use of MTX in patients with rheumatoid arthritis. 17 In this series, none of the patients had neutropenia before starting treatment with MTX. Three patients, however, had other cytopenias. In one patient, the hematocrit was 30% and increased to 39% during treatment with MTX. Two patients had thrombocytopenia with platelet counts of 72 000 and 79 000 that either increased to 96 000 (one patient) or remained stable (one patient) during treatment with MTX. Overall, the administration of MTX was well tolerated. Nine patients are still taking MTX, and five have discontinued treatment after a median of 17 weeks (range 3-39) because of hematological toxicity (n ¼ 1) or progression of GHVD (n ¼ 3, after initial response in one case). One patient decided to discontinue treatment with MTX for unclear reasons. As shown in Table 3 , adverse events recorded during treatment with MTX were limited to grade I-II toxicities and were not necessarily related to this therapy. None of the patients required blood product transfusion or treatment with hematopoietic growth factors. The patient who discontinued MTX due to hematologic toxicity was 3 months from HCT for treatment of myelodysplasia. A bone marrow aspirate showed trilineage hypocellularity before treatment with MTX was started. After three doses of MTX, the hematocrit decreased from 35 to 30%, ANC from 4.5 Â 10 9 to 0.8 Â 10 9 /l and the platelet count from 171 Â 10 9 to 83 Â 10 9 /l. After treatment with MTX was discontinued, neutrophil and platelet counts gradually recovered, and the hematocrit remained stable.
Three patients had elevated transaminase levels before starting treatment with MTX, and all the three improved during treatment (eg resolution in one, improvement by more than 50% in the other two). Six patients had impaired renal function (serum creatinine concentration 41.2 mg/dl) before starting treatment with MTX, and all six had stable renal function afterwards. In the remaining eight patients, the serum creatinine concentration was within normal limits before starting treatment with MTX, and in one of these cases, the serum creatinine concentration increased from 1.1 to 1.4 mg/dl during treatment. Three patients experienced mild nausea or fatigue for several days after MTX administration. One other patient complained of blurred vision for several hours after each dose of MTX. None of these side effects required intervention, a decrease in the dose of MTX, or discontinuation of therapy. During treatment with MTX, two patients developed pneumonia. In one case, no specific organism was identified, and the patient was treated at home with a macrolide antibiotic. In the other case, Pseudomonas aeruginosa was isolated from sputum, and the patient was hospitalized and treated with broad-spectrum intravenous antibiotics. One patient had Varicella zoster virus reactivation at a time when antiviral prophylaxis was not being given.
In total, 13 patients remain alive after a median followup of 25 weeks. One patient discontinued treatment with MTX because of progressive GVHD and later died with recurrent malignancy. In 10 patients (numbers 2, 4, 5, 6, 7, 8, 9, 10, 12, 13), chronic GVHD was adequately controlled during treatment with MTX with prednisone at doses below 1 mg/kg/every other day without the addition of other immunosuppressive agents (Table 4) . Four patients (numbers 2, 5, 8 and 13) were able to decrease or discontinue treatment with other immunosuppressive agents. Five patients (numbers 4, 6, 7, 10, 12) continued the same immunosuppressive regimen, and in four patients (numbers 1, 3, 9, 14) immunosuppressive regimen was increased (Table 4) . One patient (number 11) decided to discontinue all immunosuppressive treatments after clinical improvement, but chronic GVHD recurred 1 month later. Of note, in two patients (numbers 2 and 7) the prednisone regimen was changed from daily to alternate-day administration after improvement in manifestations of chronic GVHD.
To ensure consistency, we reviewed changes in GVHD manifestations during treatment with MTX only in the nine Table 3 Toxicity possibly related to MTX patients who had baseline and follow-up assessments at the Fred Hutchinson Cancer Research Center (Table 5) . Improvement or resolution was observed most frequently in the gastrointestinal tract (GI) (80%). Among five patients with GI disease and weight loss, three regained normal weight, while the other two had weight improvement. Scleroderma was present in six of eight patients with skin involvement. The Rodnan score decreased in two of six cases, remained unchanged in two, and increased in the other two during therapy. Improvement or resolution was also observed in the oral mucosa, eyes, and joints. Eosinophilia resolved in all four patients with this disease marker. Bronchiolitis obliterans, keratitis, and thrombocytopenia did not change during treatment with MTX in this cohort of patients. One patient had progressive joint disease, and three others developed manifestations of GVHD in previously uninvolved sites. A total of five patients experienced improvement or resolution of GVHD in at least one affected site without worsening of any other manifestation or involvement of a new site during treatment with MTX.
Discussion
Despite conventional immunosuppressive treatment, many patients with chronic GVHD continue to have significantly compromised overall survival and quality of life. We became interested in MTX for treatment of chronic GVHD because of its efficacy in patients with autoimmune diseases, the simplicity of administration, and the lower cost compared to other immunosuppressive agents.
Although the efficacy of low-dose MTX for treatment of autoimmune diseases such as rheumatoid arthritis was encouraging, we had concerns regarding adverse effects that might occur with the use of MTX in patients who had a protracted history of severe chronic GVHD after HCT.
In particular, short-and long-term side effects associated with the use of low-dose MTX include bone marrow depression, gastrointestinal symptoms, hepatic fibrosis, immune-mediated pneumonitis, infections, renal impairment and secondary malignancies. 9 In the present study, we found that MTX was well tolerated in 14 patients with refractory chronic GVHD. During a median of 25 weeks of treatment, we observed only grade 1-2 side effects, without any pulmonary or hepatic toxicity, even in patients with chronic GVHD involving the lungs or liver. In the case where administration of MTX was discontinued because of toxicity, marrow function was marginal before treatment was started. Coadministration of trimethoprim-sulfamethoxazole did not detectably increase the incidence of side effects caused by MTX, and the occurrence of infection in three of the 14 patients did not appear to exceed expectations for patients with chronic GVHD. To some extent, side effects may have been prevented by folate supplementation.
The interpretation of our results is limited by the retrospective nature of the study and the small size of the cohort. Moreover, the effect of MTX in patients with neutropenia was not tested in this study. On one hand, MTX could exacerbate neutropenia through a direct toxic effect on hematopoiesis, but, on the other hand, control of chronic GVHD through the use of MTX could enhance (Table 4) . Improvement of chronic GVHD was observed in some patients. Duration of treatment and length of followup are too short to judge the efficacy of MTX in promoting immunological tolerance in these patients. Since the patients who were treated with MTX all had long-standing, severe chronic GVHD, it remains difficult to judge the potential efficacy that this drug might have for treatment of GVHD at an earlier stage of disease. A number of Phase II trials of secondary or salvage treatments for chronic GVHD have been published, most including 40 or less patients. Most studies reported success rates of 25-50% using a wide variety of assessments and definitions of responses. 18 Toxicities of alternative treatments include increased risk of infections, cytopenias (azathioprine, Cellcept, thalidomide, monoclonal antibodies), GI toxicity (Cellcept, azathioprine, thalidomide), sedation and peripheral neuropathy (thalidomide), increased risk of cancer (azathioprine), and high cost (extracorporeal photophoresis and monoclonal antibodies). The cost of treatment is important, since the cumulative burden of medical charges is already high in patients suffering from chronic GVHD. Taking all these considerations, treatment with low-dose MTX is worthy of further investigation because of its low cost, ease of administration, and tolerability.
The preliminary results in this series of patients suggest that low-dose oral or parenteral MTX is an inexpensive and nontoxic immunosuppressive agent that might reduce the amount of steroid treatment needed to control chronic GVHD. MTX is worthy of further evaluation in prospective studies of patients with less advanced chronic GVHD.
